An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Latest Information Update: 27 May 2016
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 18 Jun 2014 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.